Skip to main content
. 2014 Mar 11;141(4):617–627. doi: 10.1111/imm.12225

Figure 5.

Figure 5

Intratracheal (i.t.) exposure to O2B-3 Fabs suppresses asthmatic responses. Mice sensitized (S) with ovalbumin (OVA) on days 0 and 14 were i.t. challenged (C) with 200 μg of OVA on days 28, 29 and 30 and with 40 μg of OVA on day 35 (a). After the fourth antigenic challenge, specific airway resistance (sRaw) (b), inflammatory cells including macrophages, lymphocytes, neutrophils and eosinophils in bronchoalveolar lavage fluid (BALF) (c), mouse mast cell protease-1 (mMCP-1) in sera, and C3a in BALF (d) were measured. One hundred and twenty micrograms of O2B-3 Fabs (S-C-O2B-3 Fabs) or control Fabs (S-C-control Fabs) were i.t. administered once 30 min before the last antigenic challenge with OVA on day 35. Non-sensitized (NS) mice given OVA were also i.t. treated with O1-10 Fabs (NS-C-O1-10 Fabs). Data are means ± SEM of five mice. *P < 0·05 versus control Fabs. Fifty micrograms of intact O1-10 alone or a mixture of 50 μg/ml intact O1-10 and 0·5, 5, 50 or 500 μg/ml O2B-3 Fabs was added to OVA coated on 96-well plates followed by further addition of anti-Fc of IgG to the plates (e). Anti-O1-10 Fabs were used as a positive control. Keyhole limpet haemocyanin was used as a control antigen. Data are representative of two independent experiments.